Arbutus Biopharma Corporation ABUS Business Segments — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeInterestEarningAsset.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's business segments — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's business segments — interest income?
- Arbutus Biopharma Corporation (ABUS) reported business segments — interest income of $815K in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — interest income changed year-over-year?
- Arbutus Biopharma Corporation's business segments — interest income decreased by 31.9% year-over-year, from $1.2M to $815K.
- What is the long-term trend for Arbutus Biopharma Corporation's business segments — interest income?
- Over 2 years (2023 to 2025), Arbutus Biopharma Corporation's business segments — interest income has grown at a -15.4% compound annual growth rate (CAGR), from $5.69M to $4.07M.
- What does business segments — interest income mean?
- This represents the revenue generated from the company's cash reserves, short-term investments, and other interest-bearing assets. It reflects the company's ability to earn a return on its liquid capital while waiting to deploy it into R&D or business development.